Mr. Diarmaid Cunningham is Chief Administrative Officer, General Counsel, Executive Vice President and Company Secretary. Mr. Cunningham joined ICON as General Counsel in November 2009 and was appointed Company Secretary in October 2011. In July 2016, Mr. Cunningham was appointed as Chief Administrative Officer in addition to his role as General Counsel. Mr. Cunningham served as Secretary to the Board of the Association of Clinical Research Organisations (ACRO) in 2013 and 2014. ACRO represents the CRO industry globally to key stakeholders including pharmaceutical, biotech and medical device companies, regulators, legislators and patient groups. Prior to joining ICON, Mr. Cunningham spent 10 years with A&L Goodbody, one of Ireland's premier corporate law firms. Mr. Cunningham graduated with a Bachelor of Business and Legal Studies from University College Dublin in 1997 and qualified as a lawyer with A&L Goodbody in 2001. In 2015, Mr. Cunningham completed the Stanford Executive Program at Stanford University in California.

Mr. George A. McMillan is Chief Commercial Officer of ICON. Mr. McMillan joined ICON in 2012 as Executive Vice President of Finance Operations, a position he held until he was appointed Chief Commercial Officer in March 2017. Prior to ICON, Mr. McMillan held senior executive positions in a variety of service and consulting companies, most recently as CFO of PharmaNet Development Group. He also served as CEO of Palladium Group, a global leader in corporate performance management software and consulting; CFO and CEO of CMGI, the internet holding company, for which he was named Mass HighTech Turnaround CEO of the Year. Mr. McMillan was also CEO of BMG Direct, the North American music distribution division of Bertelsmann, A.G., and CFO/COO of Renaissance Solutions, a strategic consulting and technology services company. George holds a Bachelor of Arts degree in Economics from Stanford University, a Doctor of Law from Harvard Law School and a Masters of Business Administration from Harvard Business School.

Dr. Nuala Murphy has been President of ICON Clinical Services at ICON since January 2014. Prior to this, Dr. Murphy served as Executive Vice President of clinical and data operations globally. Dr. Murphy has over 20 years’ experience within the pharmaceutical and CRO industry. Dr. Murphy joined ICON in 2012 from Quintiles where she led a clinical and data management workforce (since 2009). Dr. Murphy also has over a decade of experience in therapeutics having led the CNS and internal medicine project management divisions for Quintiles. Dr. Murphy served in the field of late phase clinical research at Benefit International. During her tenure, Dr. Murphy published extensively in eminent peer reviewed journals. Having graduated from Trinity College Dublin, Dr. Murphy was awarded a PhD in neurochemistry, from the Department of Cardiovascular Studies in Leeds and conducted post-doctoral research in the Department of Neuropharmacology at the Collège de France in Paris.

Mr. Colin Stanley is President of ICON Functional Services, ICON’s dedicated functional outsourcing service line. ICON’s functional services include strategic resourcing, delivered under our DOCS brand; FSP; and government sponsored research, delivered under ClinicalRM, which ICON acquired in 2016. Mr. Stanley has over 20 years of CRO industry experience. He joined ICON as a Project Manager in 2001 and since then has held a range of roles of increasing responsibility, which has enabled him to develop extensive operational, functional, and geographic expertise. His roles in ICON have included Chief Operating Officer of DOCS; Vice President, Clinical Operations, Asia Pacific; Director of Clinical Operations, US; and Head of EU Data Management. Mr. Stanley also led a global, cross-divisional, process improvement initiative within ICON. Mr. Stanley holds a Bachelor of Science degree in Biotechnology from Dublin City University.

Mr. O'Leary is ICON's Chief Information officer previous to this he held the position of President of ICON Central Laboratories. Mr. O'Leary joined the company in Feb-2001 as Manager of Data management in Dublin, Mr. O'Leary subsequently went on to set-up ICON's process improvement initiative "IMPROVE" and returned to Data Management to become EU VP of Data Management before becoming Global Head of Data Management in 2006. From 1994-2001 Mr. O'Leary worked for SmithKline Beecham and later GlaxoSmithKline and held positions in Data Management, Project Management and Resource Management. Mr. O'Leary is a graduate of Kingston University in Surrey and a Member of the Royal Society of Chemistry. Mr. O'Leary holds a Degree in Medicinal Chemistry and a Masters in Data Management.

Mr. Joe Cronin is the Executive Vice President of Human Resources, responsible for designing and implementing people practices and building organisational leadership and culture that enable ICON to execute its strategy. Mr. Cronin joined ICON in 2014. Mr. Cronin has almost 20 years of HR experience in a variety of global industries, including ten years at the Kellogg company in a number of regional and global HR leadership roles. Mr. Cronin also spent time early in his career with the General Motors (GM) Corporation and the Computer Sciences Corporation (CSC). Mr. Cronin has a Bachelor of Business degree with a major in Human Resources, from the University of Limerick.

Mr. Don Kraft is EVP of Strategic Initiatives, focused on developing ICON’s capabilities and performance as a partner to our customers. Mr. Kraft joined ICON in 2012 and served as the EVP of Human Resources before transitioning to this role in 2016.  Mr. Kraft has over 30 years of experience in the Pharmaceutical and CRO industries, including ten years as the Human Resources leader at Covance, and over ten years at Abbott Labs in a variety of leadership roles. Mr. Kraft has a wide breadth of experience in human resources and organizational development / capability building and was part of negotiating and implementing some of the industries early groundbreaking partnerships. Mr. Kraft has a Bachelor’s in Business Administration from Villanova University and a Masters in Management from Northwestern University.

Ms. Ramita Tandon leads ICON Commercialisation and Outcomes, the industry leading provider of services to help life science companies achieve market authorisation, accelerate market access, and drive market adoption. ICON Commercialisation and Outcomes delivers resources and expertise to generate and analyse real world evidence and communicate treatment safety and value to help regulators, payers, providers and patients make informed health decisions. With over two and a half decades in the drug development industry, Ms. Tandon, is a recognised executive leader for her success in broadening boundaries, innovation, and architecting lean and efficient organizational models organically and through M&A activity. Ms. Tandon is known for her dynamic and engaging leadership encouraging teams to think more provocatively and to develop innovative solutions integrating expertise across the R&D landscape and through a treatment’s entire lifecycle to optimize biopharmaceuticals’ product value. Ms. Tandon is a sought after speaker, author and thought leader with regular industry commentary on the life-sciences industry and a member of the board of the Not-for–Profit Mapi Research Trust.

Mr. Holmes leads ICON’s M&A strategy from target identification to deal close and in his time at ICON has led the acquisition of 16 companies. A member of ICON’s Leadership Team he is also involved in Strategy Development and Business Planning. Mr. Holmes joined ICON in 2005 originally as VP of Marketing and Market Development and took responsibility for Corporate Development in 2006. Between 2013 and 2017 he also had responsibility for ICON’s Investor Relations functions. Prior to joining ICON, Mr. Holmes held a number of senior roles within “Blue Chip” organisations in the IT Services and Telecommunications sectors ,including Cable and Wireless, Logica  and Microsoft. Mr. Holmes has an MBA from Smurfit Business school and is a graduate of Cambridge University and the University of East Anglia.